Contact

Adverse Events

To Report Adverse Events for Jubilant Pharmaceuticals NV products

An adverse event is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product whether or not considered related to this medicinal product.

An adverse drug reaction is a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for modification of physiological function.

A medical device incident is an incident that is due to a failure, malfunction, or deterioration in effectiveness of the device.

Healthcare professionals, consumers, clients and/or any other source can report a suspected Adverse Drug Reaction (ADR).

Collecting safety information from patients, healthcare providers and customers helps enable us to continually monitor the benefit and risk profiles of our medicinal products.

How to Report Adverse Events

To report an adverse event for Jubilant Pharmaceuticals NV products, please refer to the contact information below:

Email: pvconnect@jubl.com

For questions of health status, please consult a healthcare professional.

Countries worldwide may have specific processes in place to handle reports of adverse events. To report an adverse event, ask your health care provider for more information or contact your local health authority.

Important Note: Patients should always ask their doctors for medical advice about adverse events.

The information you provide will be processed exclusively for PV purposes to fulfil our pharmacovigilance obligations & will be protected and kept confidential in line with local regulations on data protection in the pharmacovigilance system.

Alternatively, you can complete this form:
in

Fields marked with an asterisk (*) are required.

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.